- Trials with a EudraCT protocol (646)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
646 result(s) found for: SARS-CoV-2.
Displaying page 1 of 33.
EudraCT Number: 2022-000319-30 | Sponsor Protocol Number: SECTOR | Start Date*: 2022-03-09 |
Sponsor Name:Institut Klinické a Experimentální Medicíny | ||
Full Title: Assessment of association between 3rd dose of mRNA vaccine and risk of SARS-CoV-2 infection in kidney transplant recipients, safety and immunogenicity assessment. | ||
Medical condition: SARS-CoV-2 infection in kidney transplant recipients; safety, effectiveness and immunogenicity of 3rd dose of SARS-CoV-2 mRNA vaccine. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000291-11 | Sponsor Protocol Number: IMRES | Start Date*: 2021-05-30 | |||||||||||
Sponsor Name:Medical University of Vienna | |||||||||||||
Full Title: Characterization of immune responsiveness after SARS-CoV-2 Vaccination in patients with Immunodeficiency or immunosuppressive therapy (COVID-19) | |||||||||||||
Medical condition: Vaccination against SARS-CoV-2 in immunocompromised patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005051-37 | Sponsor Protocol Number: NL78705.018.21 | Start Date*: 2021-12-06 |
Sponsor Name:Amsterdam University Medical Centre | ||
Full Title: TURN-COVID Biobank: The Dutch cohort study for the evaluation of the use of neutralizing monoclonal antibodies and other antiviral agents against SARS-CoV-2 | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002363-22 | Sponsor Protocol Number: IIV-482 | Start Date*: 2021-05-27 |
Sponsor Name:National Institute for Public Health and the Environment | ||
Full Title: Vaccination of older persons against Sars-Cov-2 and cellular immunogenicity for long term protection (participating in the Doetinchem Cohort Study) | ||
Medical condition: SARS-CoV-19, frailty | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002693-10 | Sponsor Protocol Number: VAC3_SARS-CoV2_seroconversion_study | Start Date*: 2021-07-15 |
Sponsor Name:Medical University of Vienna, Department for Internal Medicine III, Division of Rheumatology | ||
Full Title: A Phase II Study to Evaluate Safety and Efficacy to a Third Vaccination in Immunocompromised Patients with Inadequate Humoral Response after Primary mRNA SARS-CoV-2 (Covid-19) Vaccination | ||
Medical condition: Vaccination against SARS-CoV-2 in patients with immunosuppressive therapy or immunodeficiencies | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001591-15 | Sponsor Protocol Number: NL73430.091.20 | Start Date*: 2020-04-09 | |||||||||||
Sponsor Name:Radboudumc | |||||||||||||
Full Title: Reducing hospital admission of elderly in SARS-CoV-2 pandemic via the induction of trained immunity by bacillus Calmette-Guérin vaccination, a randomized controlled trial. | |||||||||||||
Medical condition: SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000617-13 | Sponsor Protocol Number: TOR-VAX | Start Date*: 2022-04-12 | |||||||||||
Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | |||||||||||||
Full Title: A prospective, randomized, controlled trial assessing the effect of conversion from Tacrolimus-antimetabolite to Tacrolimus-mTor-inhibitors based immunosuppression to booster SARS-CoV-2-specific se... | |||||||||||||
Medical condition: Seroconversion is evaluated after changing treatment from tacrolimus to tacrolimus + mTOR inhibitor in solid organ transplant patients who have not responded to the first three doses of the vaccine | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001421-31 | Sponsor Protocol Number: QUINAVID-19 | Start Date*: 2020-04-06 | |||||||||||
Sponsor Name:Sociedad Española de Farmacia Hospitalaria | |||||||||||||
Full Title: Clinical trial randomized, unblinded and controled for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals. | |||||||||||||
Medical condition: SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000842-16 | Sponsor Protocol Number: PIRVACoV | Start Date*: 2021-03-18 | ||||||||||||||||
Sponsor Name:Kristina Jakobsson | ||||||||||||||||||
Full Title: Does PFAS-exposure modify the risk of COVID-19 infection or the immunological response after vaccination against SARS-CoV-2? | ||||||||||||||||||
Medical condition: An observational study in healthy, differently PFAS-exposed subjects to check if PFAS modifies the immunological response to SARS-CoV-2 vaccination. The immunological response is quantified as SARS... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002348-57 | Sponsor Protocol Number: 2021-002348-57 | Start Date*: 2021-05-30 |
Sponsor Name:Medical University of Vienna | ||
Full Title: A Randomized, Parallel Group, Single-Blind, Phase 2 Study to Evaluate the immune response of two classes of SARS-Cov-2 Vaccines employed as Third Vaccination in Patients under current Rituximab The... | ||
Medical condition: Vaccination against SARS-CoV-2 in patients with rituximab therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001107-33 | Sponsor Protocol Number: NL76863.068.21 | Start Date*: 2021-03-10 | |||||||||||
Sponsor Name:MUMC | |||||||||||||
Full Title: SARS-CoV-2 vaccination response in patients with haematological disease | |||||||||||||
Medical condition: multiple myeloma chronic lymphocytic leukemia, non-Hodgkin lymphoma, | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002641-42 | Sponsor Protocol Number: C4591001 | Start Date*: 2020-09-04 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COV... | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000919-69 | Sponsor Protocol Number: 73249 | Start Date*: 2020-03-17 | |||||||||||
Sponsor Name:University Medical Center | |||||||||||||
Full Title: Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Guérin vaccination, a randomized controlled trial (COVID-19). | |||||||||||||
Medical condition: SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001587-29 | Sponsor Protocol Number: 02/04/2020-001 | Start Date*: 2020-04-08 | |||||||||||
Sponsor Name:Barcelona Institute for Global Health (ISGlobal) | |||||||||||||
Full Title: Hydroxychloroquine efficacy in preventing SARS-CoV-2 infection and CoVid-19 disease severity during pregnancy | |||||||||||||
Medical condition: SARS-SoV-2 infection and CoVid-19 disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003654-71 | Sponsor Protocol Number: R10933-10987-COV-2069 | Start Date*: 2020-10-06 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-Cov-2 Infection in Household Contac... | |||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001565-37 | Sponsor Protocol Number: PrEP_COVID | Start Date*: 2020-04-03 |
Sponsor Name:ISGlobal | ||
Full Title: PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID): A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL. | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000206-17 | Sponsor Protocol Number: COVID19_7 | Start Date*: 2021-03-10 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Studies of ongoing and completed SARS-CoV-2 infection (which causes COVID-19) within the healthcare in Stockholm County, with regard to vaccinations. | ||
Medical condition: Vaccination against COVID-19. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000167-69 | Sponsor Protocol Number: AIC649-02-II-01 | Start Date*: 2021-06-30 | |||||||||||
Sponsor Name:AiCuris Anti-Infective Cures AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of AIC649 in the treatment of otherwise healthy subjects with asymptomatic or mildly symptomatic SARS-CoV-2 ... | |||||||||||||
Medical condition: asymptomatic or mildly symptomatic SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002894-24 | Sponsor Protocol Number: C4671006 | Start Date*: 2021-08-23 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF-07321332/RITONAVIR IN PREVENTING SYMPTOMATI... | |||||||||||||
Medical condition: SARS-CoV-2 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) BG (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002927-39 | Sponsor Protocol Number: BOOST_TX/RESCUE_TX | Start Date*: 2021-06-13 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Preventive strategies against SARS-CoV-2 in kidney transplant recipients: Intervention A – vaccination: Single blinded randomized controlled trial on BNT162b2 or mRNA-1273 (mRNA) vs Ad26COVS1 or C... | ||
Medical condition: Intervention A - vaccination Patients following kidney transplant recipients who do not have an adequate immune response against SARS-CoV-2 following two doses of an mRNA vaccine Substudy A: kidne... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
